Biogen Inc

Most Recent

  • elderly person reading outside
    Company & Industry Overviews

    Best Stocks to Invest in Alzheimer's Research in 2021

    By Rachel Curry
  • Biogen Biotechnology lab technicians
    Healthcare

    Biogen Stock Is Rising—Will the Gains Continue after the FDA's Alzheimer’s Drug Decision?

    By Ambrish Shah
  • uploads///dECLINES
    Company & Industry Overviews

    S&P 500’s Top Losses: Why Biogen Declined

    Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.

    By Val Kensington
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///Graph
    Earnings Report

    Biogen’s Experimental Alzheimer Therapy: Limited 2Q15 Success

    On July 22, 2015, Biogen (BIIB) released data from a Phase 1b study, also called the PRIME Study, that looked at the effectiveness of its investigational Alzheimer’s drug, BIIB037.

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    How Gilead Sciences’ Gross Margin Outshines Its Peers

    Despite a year-over-year (or YoY) drop in revenues in 2Q16, Gilead Sciences (GILD) managed to earn gross margins of about 92%.

    By Margaret Patrick
  • uploads///Relative valuation
    Earnings Report

    Regeneron Continues to Trade at Premium

    Regeneron is consistently trading at a premium compared to its peers. As of January 22, it was trading at a valuation multiple of 26.67x its earnings.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Amgen Continues to Control Operating Expenses in 3Q15

    In 3Q15, Amgen recorded total operating expenses of ~$3.4 billion. This fall in expenses enabled the company to report a net profit margin of ~36.4%.

    By Margaret Patrick
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///Tysabri revenues
    Earnings Report

    How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta

    Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    How Biogen’s Tysabri and Zinbryta Performed in 1Q17

    In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets.

    By Margaret Patrick
  • uploads///lOSERS
    Healthcare

    Biogen: S&P 500’s Top Loser on January 8

    Biogen was the S&P 500’s top loser on January 8. Biogen regained strength last week and rose to ten-week high price levels.

    By Val Kensington
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///Graph
    Earnings Report

    Biogen Pursuing Investigational Candidates in Alzheimer’s Disease

    Biogen (BIIB) has entered into a licensing agreement with Bristol-Myers Squibb (BMY) for exclusive global rights for the development and commercialization of BMS-986168.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Analysts Think about Ionis

    In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Expected to See a Fall in Its Profit Margins in 2017

    Teva Pharmaceutical (TEVA) expects its 2017 non-generally accepted accounting principles (non-GAAP) earnings per share (or EPS) to fall in the range of $4.9–$5.3.

    By Margaret Patrick
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s 1Q18 Profitability

    Johnson & Johnson (JNJ) reported revenues of $20.0 billion during 1Q18, 12.6% growth as compared to revenues of $17.8 billion during 1Q17.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Regeneron’s Stock Reacts to Dupilumab Phase 3 Trials

    Regeneron Pharmaceuticals (REGN) rose 9.3% during the week ending April 1, 2016.

    By Peter Neil
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///hemophilia market size
    Company & Industry Overviews

    Could Baxalta Maintain Its Leadership in the Hemophilia Space?

    Baxalta’s (BXLT) hemophilia portfolio comprises of Advate, Adynovate, Rixubis, Recombinate, Hemofil M, Immunate, Immunine, and Prothromplex Total.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    What Will Be a Key Driver of Biogen’s Future Valuations?

    Biogen’s investigational Alzheimer’s disease drug, aducanumab, is one of the four therapies accepted in the EMA’s Priority Medicines program (or PRIME).

    By Margaret Patrick
  • uploads///hemophilia drugs
    Company & Industry Overviews

    What Are the Current Treatment Options for Hemophilia?

    Hemophilia treatment primarily includes factor replacement therapy and prolonged half-life therapy such as factor VIII or factor IX infusion.

    By Jillian Dabney
  • uploads///Graph pipeline
    Company & Industry Overviews

    BMN 270: A Big Valuation Catalyst for BioMarin

    On March 1, 2016, BioMarin received orphan drug designation for BMN 270 from the FDA. BioMarin’s stock jumped by about 6.96% the same day.

    By Jillian Dabney
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///Chart
    Earnings Report

    Novartis’s 3Q16 Estimates: Innovative Medicines Segment

    Novartis’s Innovative Medicines segment, formerly referred to as the Pharmaceutical segment, consists of products for a variety of therapeutic areas.

    By Mike Benson
  • uploads///tablets _
    Earnings Report

    Biogen Stock Trending Higher on Strong Q2 2018 Results

    Today, Biogen (BIIB) announced its earnings results for the second quarter of fiscal 2018. Here’s what you need to know.

    By Sarah Collins
  • uploads///Chart
    Earnings Report

    Novartis’s 4Q16 Estimates: Innovative Medicines Segment

    The overall contribution of the Innovative Medicines segment is ~67% of Novartis’s total revenues.

    By Mike Benson
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///jesse orrico  unsplash
    Company & Industry Overviews

    BIIB Stock Tumbles as Alzheimer Drug BAN2401 Data Failed to Impress Investors

    Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.

    By Sarah Collins
  • Why the US Moat Index Beat the S&P 500 Index in July
    Healthcare

    Why the US Moat Index Beat the S&P 500 Index in July

    Domestic moat companies, as represented by the Morningstar® Wide Moat Focus IndexSM (MWMFTR, or “U.S. Moat Index”), once again posted strong results in July.

    By VanEck
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • biib stock price reacts to biogen news
    Healthcare

    Biogen Stock Surges 44 Percent on FDA Review for Alzheimer’s Drug

    By Ambrish Shah
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth

    On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    What Are Analysts Estimating for Allergan Today?

    AGN’s analysts estimate EPS of $4.72 on revenues of $4.27 billion for 4Q17, which would be 10.5% higher YoY (year-over-year).

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Celgene’s Operating Expenses in 3Q15

    In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside AbbVie’s Analyst Recommendations in 2016

    Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene Estimates Robust Revenue in 2017

    In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

    By Margaret Patrick
  • uploads///microscope _
    Earnings Report

    BeiGene’s Q2 2018 Earnings: Reports Revenue Growth

    BeiGene (BGNE) released its Q2 2018 earnings on August 9. BGNE surpassed analysts’ estimates for revenues but missed its EPS estimates.

    By Mike Benson
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///Graph
    Company & Industry Overviews

    How Is Biogen’s Tecfidera Positioned in 2019?

    In the first quarter, Biogen reported multiple sclerosis franchise revenue of ~$2.1 billion, a flat performance on a YoY (year-over-year) basis.

    By Margaret Patrick
  • uploads///Part
    Fund Managers

    Dalio’s Bridgewater: Major Stocks Positions and New Buys in Q1

    Biogen (BIIB) was Bridgewater’s largest stock holding. Biogen contributed 0.35% of the fund’s total holdings.

    By Anuradha Garg
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///pill _
    Company & Industry Overviews

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA).

    By Daniel Collins
  • uploads///dna _
    Earnings Report

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Amgen: Analysts’ Recommendations on October 25

    Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Amgen: Expect Nearly Flat Revenues in Q3

    New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Biogen Surpassed Estimates in Q3 2018, Reports Strong Growth

    Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Analysts’ Recommendations on October 19

    For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Revenue Growth Is Expected in Q3

    Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

    By Mike Benson
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Celgene’s Financial Position before Its Third-Quarter Earnings

    Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Stock Performance and Estimates for Q3 2018

    Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Growth Rate

    Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Stock Performance in September

    On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Earnings Quality and Dividend Performance

    Eli Lilly’s dividend yield is 2.11%. Its dividend yield last year was 2.46%, and its five-year average is 2.77%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s SpotLyte and Lumivive System

    SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Developments in September

    On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

    By Mike Benson
  • uploads///addiction _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceutical in August

    On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Examining Amgen’s Revenue Trend in Q2 2018

    Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.

    By Margaret Patrick
  • uploads///microscope _
    Earnings Report

    Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

    Sarepta Therapeutics (SRPT) released its Q2 2018 earnings on August 8, surpassing analysts’ estimates for EPS and revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analysts Are Bullish on Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What Do Analysts Expect from Ionis’s Q2 2018 Earnings?

    Ionis is expected to report 30.0% growth in revenues to $135.5 million in the second quarter of 2018 as compared to $104.2 million in Q2 2017.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    What to Expect from Shire’s Q2 2018 Earnings on July 31

    Shire (SHPG) is set to release its Q2 2018 earnings on July 31. Wall Street analysts expect EPS of $3.67 on revenues of $3.8 billion.

    By Mike Benson
  • uploads///drug _
    Earnings Report

    Amgen Beats Estimates, Reports Growth in Q2 2018

    Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Amgen Announced the Phase 3 Results for ABP 710

    On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

    By Mike Benson
  • uploads///Firefish
    Company & Industry Overviews

    Risdiplam: Could It Be PTC Therapeutics’ Future Growth Driver?

    In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Biogen and Ionis Crash on PTC Therapeutics’ Promising Data

    Yesterday, PTC Therapeutics (PTCT) registered a stock price rise of ~24.6% on the positive data the company presented along with partner Roche (RHHBY) for their SMA (spinal muscular atrophy) drug risdiplam.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    Intellia Therapeutics Stock Fell 9.8% on Monday

    On June 11, Intellia stock fell 9.8% to close at $24.56 over concerns of the CRISPR-CAS9 Gene Therapy.

    By Mike Benson
  • uploads///dna _
    Healthcare

    Why Axovant Sciences Stock Jumped ~160% on Wednesday

    Axovant Sciences (AXON) stock jumped ~160.0% to the closing price of $4.55 on June 6.

    By Mike Benson
  • uploads///test
    Company & Industry Overviews

    Gilead Sciences’ Valuation in March 2018

    Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.

    By Mike Benson
  • uploads///ALKS
    Company & Industry Overviews

    Exploring Alkermes’ Financial Performance in Fiscal 2017

    Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.

    By Kenneth Smith
  • uploads///ALKS
    Company & Industry Overviews

    A Look at Alkermes’ Diabetes Product Portfolio

    According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.

    By Kenneth Smith
  • uploads///Remicade
    Company & Industry Overviews

    Performance of Johnson & Johnson’s Remicade and Stelara in 2017

    In fiscal 2017, Johnson & Johnson’s (JNJ) blockbuster drug Remicade generated revenues of $6.3 billion, which reflected an ~9.3% decline year-over-year.

    By Daniel Collins
  • uploads///LOSERS
    Healthcare

    Biogen: S&P 500’s Top Loser on February 14

    Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loser on February 14.

    By Val Kensington
  • uploads///bioverativ_businessprofile
    Company & Industry Overviews

    Exploring Bioverativ’s Business Profile and Market Presence

    Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.

    By Sarah Collins
  • uploads///Interferons
    Company & Industry Overviews

    How Biogen’s Biosimilars and Interferons Performed in 4Q17

    In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Spinraza
    Company & Industry Overviews

    How Biogen’s Spinraza Is Positioned for 2018

    In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.

    By Daniel Collins
  • uploads///Chart  Revenues
    Company & Industry Overviews

    Merck & Co.’s Quarterly Revenue Trend

    Merck & Co. (MRK) reported revenues of $10.3 billion in 3Q17, a decrease of 2% compared to 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals Post-3Q17

    Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or nontherapeutic options.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.